Karine Malagu

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity

Christine M. Chresta, Barry R. Davies, Ian Hickson et al. · Cancer Research · 2009 · 795 citations · Full text

Medicine, Oncology, Pharmacology +13

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

Kurt G. Pike, Karine Malagu, Marc Hummersone et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 206 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase

Karine Malagu, Heather M. E. Duggan, Keith Menear et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 80 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR

Keith Menear, Sylvie Gomez, Karine Malagu et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 55 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +9

A small molecule mitigates hearing loss in a mouse model of Usher syndrome III

Kumar N. Alagramam, Suhasini R. Gopal, Ruishuang Geng et al. · Nature Chemical Biology · 2016 · 46 citations

Life Sciences, Audiology, Neuroscience +13